Study Evaluating Prevenar in High-Risk Children

Wyeth is now a wholly owned subsidiary of Pfizer5,000 enrolled

Overview

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Pneumococcal Disease

Eligibility

Sex: ALLMin age: 2 YearsMax age: 5 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * High-risk children ages 2 to 5 years old Exclusion criteria: * Prior administration of Prevenar * Prior and/or concurrent administration of 23 vPs vaccine

Locations (1)

Unnamed facility

Frankfurt, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.